Aurinia Pharmaceuticals Inc. — Q1 2024 Form 10-Q
Business context and reporting period. The unaudited quarter ended March 31, 2024. Aurinia is focused on commercializing LUPKYNIS (voclosporin) for adult patients with active lupus nephritis, with Otsuka as its ex-U.S. collaboration partner. Amounts below are in U.S. dollars.
Financial and operating performance
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Total revenue | $50.3 million | $34.4 million | Up 46% |
| Net product revenue | $48.1 million | $34.3 million | Up $13.7 million, attributed mainly to greater LUPKYNIS market penetration |
| License, collaboration and royalty revenue | $2.2 million | $0.1 million | Increase mainly from Otsuka manufacturing services |
| Gross margin | Approximately 85% | Approximately 99% | Lower as cost of sales rose, including monoplant asset amortization |
| Operating loss | $13.3 million | $29.6 million | Improved by $16.3 million |
| Net loss | $10.7 million | $26.2 million | Loss per share was $0.07 versus $0.18 |
| Cash used in operations | $18.6 million | $31.7 million | Lower cash use, principally due to higher receipts from product sales and Otsuka |
As of March 31, cash, cash equivalents and restricted cash were $64.5 million, with $255.7 million in short-term investments; combined, these totaled approximately $320.1 million, versus $350.7 million at year-end 2023. Working capital was $327.2 million, down from $347.6 million. The company reported no conventional borrowings in the supplied filing text; finance lease liabilities were $81.2 million, including the monoplant lease. Total liabilities were $157.2 million. Management believes current resources can fund its current plans for at least the next few years.
LUPKYNIS patients on therapy were approximately 2,178 at quarter-end, compared with 1,731 a year earlier; the 12-month persistency rate rose to 56% from approximately 51%. Two U.S. specialty pharmacies accounted for 91% of Q1 revenue, indicating significant customer concentration.
Material changes and unusual items
- Following its strategic review, Aurinia shifted to an exclusive focus on LUPKYNIS commercial execution, reduced headcount by approximately 25%, discontinued AUR300 development, and is exploring alternative approaches for AUR200.
- Q1 restructuring expense was $6.7 million, primarily severance, one-time benefits and contract termination costs. Management said most planned restructuring costs were recorded in the quarter.
- Management expects annual cost savings of $50 million to $55 million, with 75% expected to be realized in 2024, excluding the one-time restructuring charge.
- Other income, net was $4.1 million, primarily reflecting foreign-exchange remeasurement of the Swiss-franc-denominated monoplant lease liability. The quarter also included $1.3 million of lease interest expense.
- The company repurchased approximately 2.4 million shares for $13.4 million, including transaction costs, during the quarter. Its authorized program is up to $150 million; an additional approximately 1.0 million shares were repurchased for $5.2 million from April 1 through April 30.
Outlook, risks and contingencies
Aurinia estimates average annualized net realizable LUPKYNIS revenue per patient of approximately $70,000 to $75,000; this is an estimate, not a reported realized revenue figure. Otsuka filed a Japanese voclosporin application in November 2023. Aurinia is eligible for a $10 million payment upon approval, which the filing says is anticipated in the second half of 2024, plus low double-digit royalties on Japanese net sales after launch.
Key risks include dependence on LUPKYNIS and a small number of customers, the ability to sustain patient starts and persistency, execution of projected savings, product supply and manufacturing costs, and uncertainty in regulatory and commercial outcomes. A 10% Swiss-franc fluctuation would change the reported monoplant lease liability by approximately $8.1 million. A hypothetical 100-basis-point decrease in investment rates would reduce annual investment interest by approximately $2.6 million. The filing reports no material change in risk factors or material litigation developments; management said ordinary-course contingencies are not expected to materially affect financial position. Forward-looking estimates are subject to risks and may differ from actual results.
Important facts for investors to verify
- Whether patient growth and persistency continue to support product revenue growth, and how revenue concentration evolves.
- Whether gross margin stabilizes as sales grow and the monoplant lease and manufacturing costs flow through results.
- Whether the $50 million to $55 million annual savings target is achieved, including the expected 2024 realization, and whether further restructuring costs arise.
- How cash resources change with operating needs, lease payments, commercial commitments and the ongoing share repurchase program.
- The timing and outcome of Japanese regulatory review, the potential $10 million milestone and any resulting royalties.